Mercury Biopharmaceutical Corporation (TPEX:6932)

Market Cap	6.12B
Revenue (ttm)	5.75M
Net Income (ttm)	-43.41M
Shares Out	421.85M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	170,965
Average Volume	281,804
Open	14.20
Previous Close	14.50
Day's Range	14.20 - 15.05
52-Week Range	10.10 - 17.60
Beta	-2.67
RSI	41.41
Earnings Date	Apr 24, 2025

About Mercury Biopharmaceutical

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6932

Financial Performance

In 2023, Mercury Biopharmaceutical's revenue was 1.03 million, a decrease of -61.46% compared to the previous year's 2.68 million. Losses were -43.82 million, 40.2% more than in 2022.